Kiadis and Gulf Coast Regional Blood Center announce col­lab­o­ra­tion to pro­vide uni­ver­sal donor mate­r­i­al for K-NK cell ther­a­py pro­grams

Collaboration marks first con­trac­tu­al part­ner­ship with sup­pli­er of uni­ver­sal donor mate­r­i­al 

Amsterdam, The Netherlands, September 28, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive NK-cell-based med­i­cines for the treat­ment of life-threat­en­ing dis­eases and Gulf Coast Regional Blood Center (GCRBC), a pri­ma­ry sup­pli­er of blood com­po­nents to more than 170 hos­pi­tals and health care facil­i­ties, today announce a col­lab­o­ra­tion under which GCRBC will sup­ply uni­ver­sal donor start­ing mate­r­i­al for the man­u­fac­ture of Kiadis’ off-the-shelf K-NK Natural Killer (NK) cell ther­a­pies in the United States.

Kiadis’ pro­pri­etary off-the-shelf K-NK cell plat­form is based on NK cells from unique uni­ver­sal donors. This col­lab­o­ra­tion will pro­vide Kiadis with an ongo­ing sup­ply of start­ing mate­r­i­al need­ed for clin­i­cal sup­ply and research and devel­op­ment. The Company is devel­op­ing mul­ti­ple K-NK pro­grams uti­liz­ing uni­ver­sal donor start­ing mate­r­i­al.

Arthur Lahr, chief exec­u­tive offi­cer of Kiadis, com­ment­ed, “Our col­lab­o­ra­tion with Gulf Coast Regional Blood Center gives us access to their broad donor net­work to iden­ti­fy uni­ver­sal donors using our pro­pri­etary algo­rithm and selec­tion ana­lyt­ics. We then take the donor immune cells as source mate­r­i­al to pro­duce off-the-shelf K-NK cells. This col­lab­o­ra­tion fur­ther helps us ensure a con­tin­ued sup­ply of uni­ver­sal donor mate­r­i­al for our K-NK cell ther­a­py pro­grams.”

Hope Guidry-Groves, Cellular Life Solutions Director at Gulf Coast Regional Blood Center, stat­ed, “Our mis­sion is to part­ner with the com­mu­ni­ty to help save and sus­tain lives by pro­vid­ing a safe sup­ply of blood, bio­ther­a­pies and relat­ed ser­vices.  With our his­to­ry of excel­lence and proven exper­tise, we can help dri­ve more treat­ment options to patients through advanced blood ther­a­pies. By help­ing researchers locate will­ing and eli­gi­ble par­tic­i­pants for these spe­cial­ized col­lec­tions, we are doing our part in bring­ing new hope to patients.”

Leave a Reply

Your email address will not be published. Required fields are marked *